Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Vacuum Erection Device Brands

Timm Medical Osbon ErecAid, Pos-T-Vac, Augusta & generics

Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
FDA-cleared as Class II medical devices (Rx and OTC variants)

Reference only. Not medical advice.

What can go wrong

Generally safe. Common issues: a cool/hinged erection pivoting at the base, petechiae/bruising, numbness, trapped ejaculation, and discomfort. The constriction ring must not be left on beyond ~30 minutes (ischemia risk). Men on anticoagulants or with bleeding/sickle disorders need caution. The 'penis pump' OTC market also includes low-quality novelty devices that differ from clinical VEDs.

This is something to take to a clinician. The Atlas can tell you what is known about vacuum erection device brands in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Vacuum erection devices (VEDs, 'penis pumps') create an erection mechanically using negative pressure, with a constriction ring to maintain it. The legacy clinical brand is Timm Medical's Osbon ErecAid (also Pos-T-Vac); Augusta Medical and many generic/OTC pumps also sell into the market. VEDs are AUA-recognized, non-invasive, drug-free, and especially important in post-prostatectomy penile rehabilitation, where they help oxygenate cavernosal tissue and limit length loss.

Decades-old, drug-free, and central to post-prostatectomy rehab.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • On-demand mechanical erection
  • Post-prostatectomy penile rehabilitation
  • PDE5-inhibitor non-responders
  • Combination with other therapies

How it works

A cylinder placed over the penis is evacuated by a manual or battery pump, drawing blood into the corpora to produce an erection; a constriction ring slipped to the base maintains rigidity for intercourse (the ring should be removed within ~30 minutes). In rehabilitation, repeated vacuum-induced engorgement is thought to improve tissue oxygenation and reduce the cavernosal fibrosis and length loss that follow nerve-sparing prostatectomy.

What people get wrong

  • Often saidPenis pumps permanently enlarge the penis

    ActuallyClinical VEDs treat ED and aid rehabilitation; they do not produce permanent enlargement. Enlargement marketing on novelty pumps is not supported.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

How we got here

Vacuum therapy for impotence was patented and commercialized by Geddings Osbon (the Osbon ErecAid) and entered urologic practice in the 1980s, predating oral PDE5 inhibitors. It became a mainstay non-drug option and, later, a core element of post-prostatectomy rehabilitation protocols.

Set against the alternatives

Versus drugs, VEDs are drug-free and avoid the nitrate contraindication, but many men find them cumbersome; satisfaction/adherence is lower than with effective oral therapy. In rehabilitation, VEDs are frequently combined with PDE5 inhibitors and/or injection. Clinical brands (Osbon ErecAid) differ in quality and ring systems from generic OTC pumps.

At a glance

Legacy clinical brand
Timm Medical Osbon ErecAid (also Pos-T-Vac)
Mechanism
Negative-pressure chamber + constriction ring
Key market
Post-prostatectomy penile rehabilitation
Status
FDA-cleared Class II; Rx and OTC versions exist

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Vacuum Erection Device Brands. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.